Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine whether the combination of Ulocuplumab and Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung cancer.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Bristol-Myers Squibb
NCT06132828 · Solid Tumor
NCT04570423 · Solid Tumors, Lymphoma
NCT06144671 · Solid Tumor, Adult
NCT07177937 · Small Cell Lung Cancer, Melanoma, and more
NCT06926283 · Prostate Cancer, Other Solid Tumors, and more
University Of Colorado Hosp
Aurora, Colorado
Indiana University Health
Indianapolis, Indiana
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Baltimore, Maryland
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions